-
Sector Analysis
B-Cell Non-Hodgkin's Lymphoma Epidemiology Analysis and Forecast to 2033
Non-Hodgkin’s lymphoma (NHL) represents a group of cancers that develop in the lymphatic system. Individuals with NHL experience uncontrolled malignant white blood cells, rendering the immune system incapable of effectively fighting off infections. Among all malignant lymphomas, the 90% are composed of NHL, making it among the most prevalent hematological adult cancers (Ekströ Smedby et al., 2008). NHL is segmented by its histology into B-cell, T-cell, and natural killer lymphocyte lymphoma, with B-cell lymphoma constituting 80─85% of the three subtypes....
-
Product Insights
Squamous Non-Small Cell Lung Cancer Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Squamous Non-Small Cell Lung Cancer - Global Clinical Trials Review, 2025" provides an overview of Squamous Non-Small Cell Lung Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Squamous Non-Small Cell Lung Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Sector Analysis
Myelodysplastic Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Myelodysplastic Syndrome Therapeutics. - GlobalData epidemiologists estimate that there were 498,757 diagnosed prevalent cases of Myelodysplastic Syndrome (MDS) infection in 2024, which is expected to increase slightly to 557,730 diagnosed prevalent cases by 2029. - MDS is managed through a combination of supportive care, chemotherapy, and targeted therapies. - The MDS pipeline holds 262 molecules, with two assets in the pre-registration stage, 16 assets in Phase...
-
Product Insights
Acute Lymphocytic Leukemia (ALL) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Global Clinical Trials Review, 2025" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7...
-
Product Insights
Bladder Cancer Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Bladder Cancer - Global Clinical Trials Review, 2025" provides an overview of Bladder Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Bladder Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Prostate Cancer Epidemiology Analysis and Forecast to 2033
Prostate cancer is a malignancy in the prostate gland, which is located below the bladder and in front of the rectum in males. Worldwide, about 1.4 million men were diagnosed with prostate cancer in 2020 (Wang et al., 2022). In the US, prostate cancer is the most common cancer in men after skin cancer, and it is the third most common cause of cancer death in men (Siegel et al., 2020). Approximately one in seven American men are diagnosed with...
-
Sector Analysis
Engineered Exosomes - Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals
Engineered exosomes are small vesicles secreted by cells that have been modified to carry specific cargo, such as drugs or therapeutic molecules. These engineered exosomes have shown great potential as delivery vehicles for targeted therapy in various diseases, including cancer, neurodegenerative disorders, and inflammatory conditions. By loading exosomes with therapeutic agents and targeting them to specific cells or tissues, researchers aim to improve the efficacy and reduce the side effects of traditional drug delivery methods. This emerging field of research...
-
Product Insights
Myelodysplastic Syndrome Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Myelodysplastic Syndrome - Global Clinical Trials Review, 2025" provides an overview of Myelodysplastic Syndrome Clinical trials scenario. This report provides top line data relating to the clinical trials on Myelodysplastic Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Bile Duct Cancer (Cholangiocarcinoma) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
GlobalData's clinical trial report, “Bile Duct Cancer (Cholangiocarcinoma) - Global Clinical Trials Review, 2024" provides an overview of Bile Duct Cancer (Cholangiocarcinoma) Clinical trials scenario. This report provides top line data relating to the clinical trials on Bile Duct Cancer (Cholangiocarcinoma). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Sector Analysis
B-cell Depletion - Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals
B-Cell Depletion Report Overview B cell depletion is a therapeutic strategy to reduce the number of B lymphocytes, which play a crucial role in autoimmune diseases and certain cancers. The approach primarily treats conditions like rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus. Furthermore, the underlying patent publication growth shows an accelerating innovation trend within this field. Big pharma dominates the patent activity followed by private companies, startups, and small biotech. B-cell depletion is an accelerating innovation among 80+ innovation...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.